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ABSTRACT
As prostate cancer is the second leading cause of death after lung cancer, several diagnostic strategies have been introduced in
recent years. Among these prostate-specific antigens, it is widely recognized that this is the simplest and most common clinical
endpoint - genetic instability is part of the oncogenic process. Gene mutations involved in DNA repair mechanisms may
promote this genetic instability and participate in oncogenesis and metastatic progression. In prostate cancer, abnormalities in
DNA repair are primarily due to somatic or constitutional mutations in the BRCA1/2 genes. Treatment options for prostate
cancer are currently widely discussed in the media and by urological associations. Focal therapy is expected to have the same
oncological efficacy as whole gland therapy with fewer side effects. Accurate diagnosis with multipara metric magnetic
resonance imaging (MRI). In this review we examine the various studies described the molecular targets for personalized
prostate cancer therapy.
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INTRODUCTION
Personalized medicine emerges to apply the right
treatment at the right time to each individual by seeking
for his characteristics such as genetic profile. It use a lot of
resources in order to find the right diagnostic, prognostic
and predictive [1]. Individualized medicine had already
demonstrate her efficacy in such specialties, like
measuring... disease, we will furthermore understand how
personalized medicine treat the prostate cancer[2], we will
focus on the application of personalized medicine in
cancer, particularly in prostate cancer.
Commonly, prostate cancer (PC) cause a significant
amount of men’s death in western societies, and it's the
most spread type of adult malignancies in the whole world
[3]. PC is a heterogeneous disease at both the clinical and
molecular level; however, the agents causing the onset of
prostate cancer are unknown. A small number of risk
factors have been identified (Age, Endogenous hormone
balance, Genetic (predisposing) factors and Environment
factors), although they are supported by a large number of
small studies, leading to contradictory or inconclusive
results[4]. To choose the appropriated therapeutic option,

Health Sci.2020;1:4p

evaluation of life-expectancy is essential to offer an
optimal individualized treatment. It is essential to take into
account the patients' aspirations before starting any
diagnostic and therapeutic approach (Mongiat-Artus and
Avenin 2017). The objective of our current review is to
present the molecular targets for personalized prostate
cancer therapy.
INCIDENCE AND MORTALITY
According to data from general cancer registries, grouped
by Francium [5], the incidence is increasing regularly
every year, an annual increase in incidence of 7.9% was
noted between 1995 and 2000 (Figure 1). Incidence
increases with age; the risk to get PC before age 50 is very
low (0.3%) [6].The median age at diagnosis is declining to
70 years in 2004 old as compared to 74 years old in 1995
[7], with 10,004 deaths in 2000. The PC death rate
increases by 0.17% per year. The increase of deaths
number is explained mainly by the ageing of the
population [5].
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Figure 1: PC incidence and Mortality
PROSTATE-SPECIFIC ANTIGEN (PSA)
PSA, also renowned as kallikrein-3, is a glycoprotein
developed by the prostate. Its function is to liquefy the
serum and promote sperm movement and dissolution of
cervical mucus. PSA was uncovered by Richard Ablin in
the 1970s; according to his conclusions, it then led to
"Catalona et al. (1991) recognized the possibility of early
detection of PC. Reported a group of 1,653 men who
underwent a PSA test in addition to a digital rectal
exam.[8]; PSA is the most abundant protein in seminal
fluid; concentration of PSA in the seminal fluid was 1000
times higher than its concentration in serum. It has a low
molecular weight protease composed of 240 amino acids
[10]. Protein dosage enable PC detection, but several
aspects must be considered [9] the threshold value of 4
ng/ml is conventionally used. A value threshold for total
PSA < 4 ng/ml is proposed for ages less than 70 years or
for at-risk groups. The threshold of 3 ng/ml is commonly
used in screening protocols [7]. The PSA dosage has upset
the management of PC at all stages of development. PSA
supplies prognosis at all stages of the PC, both before and
after treatment, regardless of the treatment chosen. The
PSA simplified the initial extension assessment and
monitoring,[9]
The prescription of PSAT for early detection has made
which has been the subject of much criticism. In contrast,
the authorities most opposed to its use have returned to the
issue. Their restriction due to new data including new
support with in particular the monitoring of active PC.
Indeed, the correct prescription of PSAT and PSAL is
comprehensible in the right patient management to evade
over- or under-treatment. The reasoned prescriptions
based on initial PSAT and age values improve marker
medical service rendering. It should be noted that novel
candidate biomarkers have shown discriminating values
higher than the % PSAL in this indication and must be
assessed with imaging for early detection.[11].
BRCA1 AND BRCA2 MUTATION
BRCA1 was firstly Jewish Breast Cancer Patients and
Frequency The overall distribution of Ashkenazi Jews is
~1%. This variant was also found in non-Ashkenazi,
Spanish and British Jewish communities. For PC, BRCA2
is significantly associated with an increased risk PC of
Ashkenazi Jews. In a large-scale controlled study, 251
unselected Ashkenazi PC and 1,472 healthy control men
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were recruited [12].The presence of BRCA1 / 2 mutations
is related to the presence of mutation characteristics
associated with HR deficiency in adenocarcinoma of the
prostate. The HRD profile has also been detected in some
patients without gremlin or somatic mutations in BRCA1
/ 2 / other HR-related genes. This is likely to define a
subset of PC patients accurately identified by the WGS
data, and these patients are likely to benefit from PARP
inhibitors or platinum therapy [13]. The presence of
BRCA1 / 2 mutations is related to the presence of mutation
characteristics associated with HR deficiency in
adenocarcinoma of the prostate. The HRD profile has also
been revealed in some patients without gremlin or somatic
mutations in BRCA1 / 2 / other HR-related genes. This is
likely to define a subset of PC patients accurately
identified by the WGS data, and these patients are likely to
benefit from PARP inhibitors or platinum therapy [14].
Among BRCA mutation carriers, the risk of PC is 1.90
times higher. This increased risk of PC is primarily
attributed to the 2.64 times higher risk of BRCA2 carriers,
and the risk of PC in BRCA1 carriers is 1.35 times higher.
The frequency of the BRCA2 mutation in PC patients is
higher than BRCA1 mutation. BRCA2 mutations are the
most associated to PC mortality. BRCA mutations can
stratify high-risk patients and guide clinical strategies to
more effectively treat patients with DCP [15]. Despite
advances in the treatment of castration-resistant PC
(CRPC), options remain limited and incurable. PC rests
one of the most deadly cancers in men. The discovery of
new therapeutic targets is necessary to improve the result
of men with metastatic PC. Precision/personalized
medicine has produced innovative prospects to discover
therapeutic targets. Next generation sequencing analysis
increases the identification of potential relevant tumor
mutations [16].
PERSONALIZED MEDICINE
In the field of health, nothing better than so-called
personalized medicine to illustrate the general debate on
the impact of invention. Faced with the marketing
commitments linked to the commercialization of certain
biomarkers, "make every therapy a therapy". "Unique",
scientists have the right to recall that so-called
personalized medicine does not literally mean creating
unique and personalized medicines and treatment
procedures for each patient, but the ability to classify
2
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individuals into subgroups sensitive to infection or
response for specific therapies [17]. The use of biomarkers
in oncology may guide to benefit from more effective and
less toxic cancer treatments. The rise of molecular biology
has brought about dramatic changes in the development of
targeted molecular therapies [18]. These two genes play a
key role in the repair of double-stranded DNA through
homologous recombination, a faithful repair mechanism.
If the function of the gene is lost, the cells are deficient
homologous recombination and genetically unstable, this
sensitivity can be used in certain targeted therapies. The
lethality principle describes a situation in which a
defective gene is compatible with cell survival, but it is
combined to a second defect. It causes cell death as
described by Hartwell et al in therapeutic targeting of
tumors. So far, although ovarian cancer has been widely
studied in PC. In practical applications, ovarian cancer has
been the main focus of synthetic lethal research [19].
However, there are an obstacles to overcome. The
molecular profile of a tumor is not a substitute for
histology, as demonstrated by the lack of clinical benefit
seen in the SAFIR-01 and SHIVA tests. The functional
impact of many mutations remains unknown. The
complexity of interpreting genomic profiles is influenced
by the tumor purity of the sample, detection thresholds, or
available libraries, which complicate to overcome in order
to identify the real drivers of oncogenic and overcoming
treatment resistance. Epigenetics presents a novel track to
explore, an additional however unavoidable dimension for
the understanding of tumor biology [20].

less performed few years ago, is now mainly performed
with robotic assistance and although the level of evidence
is controversial. Its worldwide use is based on undeniable
ease of use. Finally, between active surveillance and
validated conventional treatments for PC (total
prostatectomy, brachytherapy and radiotherapy) there is
certainly room for care may be more acceptable to patients
than active surveillance and less morbid than conventional
treatments and represents a focal treatment. In contrast,
pending the results of randomized trials, supervision of
focal treatment practices is necessary[21].Neither neo
adjuvant treatment has exposed a benefit by terms of
progression-free survival, specific or overall survival, but
the question deserves to be asked again for high-risk and
locally advanced tumors with new hormonal
treatments[6].

CONCLUSION
In recent years, active surveillance has been proposed as
the standard for PC management. Prostatectomy, although
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